Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Frank I. Tarazi, PH.D.

TitleAssociate Professor of Psychiatry
InstitutionMcLean Hospital
DepartmentPsychiatry
AddressMclean Hospital
Mailman Research Ctr 306-C
115 Mill St
Belmont MA 02478
Phone617/855-3176
Fax617/855-3479

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Tarazi FI, Neill JC. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov. 2013 Jan; 8(1):93-103.
    View in: PubMed
  2. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep; 13(13):1911-22.
    View in: PubMed
  3. Adler LA, Kroon RA, Stein M, Shahid M, Tarazi FI, Szegedi A, Schipper J, Cazorla P. A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2012 Dec 1; 72(11):971-7.
    View in: PubMed
  4. Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012 Jun; 66(6):522-32.
    View in: PubMed
  5. Liégeois JF, Deville M, Dilly S, Lamy C, Mangin F, Résimont M, Tarazi FI. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. J Med Chem. 2012 Feb 23; 55(4):1572-82.
    View in: PubMed
  6. Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012 Apr; 134(1):8-25.
    View in: PubMed
  7. Choi YK, Tarazi FI. Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia. BMB Rep. 2010 Sep; 43(9):593-8.
    View in: PubMed
  8. Wong EH, Tarazi FI, Shahid M. The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol Ther. 2010 May; 126(2):173-85.
    View in: PubMed
  9. Ardayfio PA, Leung A, Park J, Hwang DY, Moran-Gates T, Choi YK, Carlezon WA, Tarazi FI, Kim KS. Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs. Neuroscience. 2010 Mar 17; 166(2):391-6.
    View in: PubMed
  10. Tarazi FI, Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today (Barc). 2009 Dec; 45(12):865-76.
    View in: PubMed
  11. Choi YK, Moran-Gates T, Gardner MP, Tarazi FI. Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats. Eur Neuropsychopharmacol. 2010 Mar; 20(3):187-94.
    View in: PubMed
  12. Choi YK, Wong EH, Henry B, Shahid M, Tarazi FI. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol. 2010 Apr; 13(3):405-10.
    View in: PubMed
  13. Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI. Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J Mol Neurosci. 2009 Jul; 38(3):227-35.
    View in: PubMed
  14. Tarazi FI, Choi YK, Gardner M, Wong EH, Henry B, Shahid M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse. 2009 May; 63(5):413-20.
    View in: PubMed
  15. Si YG, Choi YK, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1; 19(1):51-3.
    View in: PubMed
  16. Choi YK, Gardner MP, Tarazi FI. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol. 2009 Feb; 19(2):77-84.
    View in: PubMed
  17. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol. 2010 Mar; 24(3):341-8.
    View in: PubMed
  18. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. Bioorg Med Chem Lett. 2008 Jul 15; 18(14):3971-3.
    View in: PubMed
  19. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl). 2008 May; 198(1):103-11.
    View in: PubMed
  20. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. J Med Chem. 2008 Feb 28; 51(4):983-7.
    View in: PubMed
  21. Adrover E, Berger MA, Pérez AA, Tarazi FI, Antonelli MC. Effects of prenatal stress on dopamine D2 receptor asymmetry in rat brain. Synapse. 2007 Jun; 61(6):459-62.
    View in: PubMed
  22. Si YG, Gardner MP, Tarazi FI, Baldessarini RJ, Neumeyer JL. R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1; 17(15):4128-30.
    View in: PubMed
  23. Tarazi FI, Moran-Gates T, Gardner MP, Graulich A, Lamy C, Liégeois JF. Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors. J Mol Neurosci. 2007; 32(3):192-8.
    View in: PubMed
  24. Moran-Gates T, Grady C, Shik Park Y, Baldessarini RJ, Tarazi FI. Effects of risperidone on dopamine receptor subtypes in developing rat brain. Eur Neuropsychopharmacol. 2007 May-Jun; 17(6-7):448-55.
    View in: PubMed
  25. Tamagnan GD, Brenner E, Alagille D, Staley JK, Haile C, Koren A, Early M, Baldwin RM, Tarazi FI, Baldessarini RJ, Jarkas N, Goodman MM, Seibyl JP. Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15; 17(2):533-7.
    View in: PubMed
  26. Moran-Gates T, Massari C, Graulich A, Liégeois JF, Tarazi FI. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. J Neurosci Res. 2006 Aug 15; 84(3):675-82.
    View in: PubMed
  27. Moran-Gates T, Gan L, Park YS, Zhang K, Baldessarini RJ, Tarazi FI. Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects. Synapse. 2006 Feb; 59(2):92-100.
    View in: PubMed
  28. Moran-Gates T, Zhang K, Baldessarini RJ, Tarazi FI. Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2005 Sep; 8(3):439-44.
    View in: PubMed
  29. Hwang DY, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI, Chesselet MF, Kim KS. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci. 2005 Feb 23; 25(8):2132-7.
    View in: PubMed
  30. Zhang K, Grady CJ, Tsapakis EM, Andersen SL, Tarazi FI, Baldessarini RJ. Regulation of working memory by dopamine D4 receptor in rats. Neuropsychopharmacology. 2004 Sep; 29(9):1648-55.
    View in: PubMed
  31. Tarazi FI, Zhang K, Baldessarini RJ. Dopamine D4 receptors: beyond schizophrenia. J Recept Signal Transduct Res. 2004 Aug; 24(3):131-47.
    View in: PubMed
  32. Barros VG, Berger MA, Martijena ID, Sarchi MI, Pérez AA, Molina VA, Tarazi FI, Antonelli MC. Early adoption modifies the effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. J Neurosci Res. 2004 May 15; 76(4):488-96.
    View in: PubMed
  33. Gan L, Falzone TL, Zhang K, Rubinstein M, Baldessarini RJ, Tarazi FI. Enhanced expression of dopamine D(1) and glutamate NMDA receptors in dopamine D(4) receptor knockout mice. J Mol Neurosci. 2004; 22(3):167-78.
    View in: PubMed
  34. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2003 Sep; 306(3):1145-51.
    View in: PubMed
  35. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Animal models of attention-deficit hyperactivity disorder. Brain Res Brain Res Rev. 2003 Apr; 42(1):1-21.
    View in: PubMed
  36. Balcioglu A, Zhang K, Tarazi FI. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience. 2003; 119(4):1045-53.
    View in: PubMed
  37. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide. 2002 Dec; 7(4):297-300.
    View in: PubMed
  38. Berger MA, Barros VG, Sarchi MI, Tarazi FI, Antonelli MC. Long-term effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. Neurochem Res. 2002 Nov; 27(11):1525-33.
    View in: PubMed
  39. Zhang K, Davids E, Tarazi FI, Baldessarini RJ. Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. Brain Res Dev Brain Res. 2002 Aug 30; 137(2):135-8.
    View in: PubMed
  40. Davids E, Hevers W, Dämgen K, Zhang K, Tarazi FI, Lüddens H. Organotypic rat cerebellar slice culture as a model to analyze the molecular pharmacology of GABAA receptors. Eur Neuropsychopharmacol. 2002 Jun; 12(3):201-8.
    View in: PubMed
  41. Davids E, Zhang K, Kula NS, Tarazi FI, Baldessarini RJ. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther. 2002 Jun; 301(3):1097-102.
    View in: PubMed
  42. Zhang K, Tarazi FI, Davids E, Baldessarini RJ. Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning. Neuropsychopharmacology. 2002 May; 26(5):625-33.
    View in: PubMed
  43. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl). 2002 May; 161(3):263-70.
    View in: PubMed
  44. Zhang K, Davids E, Tarazi FI, Baldessarini RJ. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions. Psychopharmacology (Berl). 2002 Apr; 161(1):100-6.
    View in: PubMed
  45. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002; 16(1):23-45.
    View in: PubMed
  46. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl). 2002 Feb; 160(1):92-8.
    View in: PubMed
  47. Zhang K, Tarazi FI, Baldessarini RJ. Role of dopamine D(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology. 2001 Nov; 25(5):624-32.
    View in: PubMed
  48. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001 May; 297(2):711-7.
    View in: PubMed
  49. Zhang K, Tarazi FI, Baldessarini RJ. Nigrostriatal dopaminergic denervation enhances dopamine D(4) receptor binding in rat caudate-putamen. Pharmacol Biochem Behav. 2001 May-Jun; 69(1-2):111-6.
    View in: PubMed
  50. Tarazi FI, Zhang K, Baldessarini RJ. Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain Res. 2000 Oct 20; 881(1):69-72.
    View in: PubMed
  51. Tarazi FI, Kula NS, Zhang K, Baldessarini RJ. Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ. Neuropharmacology. 2000 Aug 23; 39(11):2133-8.
    View in: PubMed
  52. Tarazi FI, Zhang K, Baldessarini RJ. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neurosci Lett. 2000 Jun 23; 287(2):81-4.
    View in: PubMed
  53. Tarazi FI, Baldessarini RJ. Comparative postnatal development of dopamine D(1), D(2) and D(4) receptors in rat forebrain. Int J Dev Neurosci. 2000 Feb; 18(1):29-37.
    View in: PubMed
  54. Zhang K, Tarazi FI, Baldessarini RJ. Dopamine D(4) receptors in rat forebrain: unchanged with amphetamine-induced behavioral sensitization. Neuroscience. 2000; 97(2):211-3.
    View in: PubMed
  55. Zhang K, Tarazi FI, Campbell A, Baldessarini RJ. GABA(B) receptors: altered coupling to G-proteins in rats sensitized to amphetamine. Neuroscience. 2000; 101(1):5-10.
    View in: PubMed
  56. Kula NS, Baldessarini RJ, Tarazi FI, Fisser R, Wang S, Trometer J, Neumeyer JL. [3H]beta-CIT: a radioligand for dopamine transporters in rat brain tissue. Eur J Pharmacol. 1999 Dec 3; 385(2-3):291-4.
    View in: PubMed
  57. Zhang K, Weiss NT, Tarazi FI, Kula NS, Baldessarini RJ. Effects of alkylating agents on dopamine D(3) receptors in rat brain: selective protection by dopamine. Brain Res. 1999 Nov 13; 847(1):32-7.
    View in: PubMed
  58. Tarazi FI, Baldessarini RJ. Dopamine D4 receptors: significance for molecular psychiatry at the millennium. Mol Psychiatry. 1999 Nov; 4(6):529-38.
    View in: PubMed
  59. Zhang K, Tarazi FI, Kula NS, Baldessarini RJ, Neumeyer JL. Selective alkylatation of dopamine D2 and D4 receptors in rat brain by N-(p-isothiocyanatophenethyl)spiperone. Neurosci Lett. 1999 Oct 29; 274(3):155-8.
    View in: PubMed
  60. Tarazi F, Dvorak MF, Wing PC. Spinal injuries in skiers and snowboarders. Am J Sports Med. 1999 Mar-Apr; 27(2):177-80.
    View in: PubMed
  61. Tarazi FI, Baldessarini RJ. Brain dopamine D(4) receptors: basic and clinical status. Int J Neuropsychopharmacol. 1999 Mar; 2(1):41-58.
    View in: PubMed
  62. Tarazi FI, Baldessarini RJ. Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions. J Neurosci Res. 1999 Feb 15; 55(4):401-10.
    View in: PubMed
  63. Kula NS, Tarazi FI, Baldessarini RJ, Xu L, Bakthavachalam V, Pounds S, True CD. Neuropharmacological assessment of potential dopamine D4 receptor-selective radioligands. Eur J Pharmacol. 1999 Feb 12; 367(1):139-42.
    View in: PubMed
  64. Lee H, Tarazi FI, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sci. 1999; 64(18):1595-602.
    View in: PubMed
  65. Tarazi FI, Tomasini EC, Baldessarini RJ. Postnatal development of dopamine D1-like receptors in rat cortical and striatolimbic brain regions: An autoradiographic study. Dev Neurosci. 1999; 21(1):43-9.
    View in: PubMed
  66. Tarazi FI, Campbell A, Baldessarini RJ. Effects of hippocampal kainic acid lesions on striatolimbic dopamine D1-, D2-, and D4-like receptors. Neuroscience. 1998 Nov; 87(1):1-4.
    View in: PubMed
  67. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ. Localization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: comparison of NMDA, AMPA, and kainate receptors. Synapse. 1998 Oct; 30(2):227-35.
    View in: PubMed
  68. Tarazi FI, Tomasini EC, Baldessarini RJ. Postnatal development of dopamine D4-like receptors in rat forebrain regions: comparison with D2-like receptors. Brain Res Dev Brain Res. 1998 Oct 1; 110(2):227-33.
    View in: PubMed
  69. Tarazi FI, Tomasini EC, Baldessarini RJ. Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus accumbens septi. Neurosci Lett. 1998 Sep 18; 254(1):21-4.
    View in: PubMed
  70. Tarazi FI, Campbell A, Baldessarini RJ. Effects of hippocampal lesions on striatolimbic ionotropic glutamatergic receptors. Neurosci Lett. 1998 Jun 26; 250(1):13-6.
    View in: PubMed
  71. Tarazi FI, Yeghiayan SK, Neumeyer JL, Baldessarini RJ. Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors: common targets for typical and atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1998 May; 22(4):693-707.
    View in: PubMed
  72. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ. Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience. 1998 Mar; 83(1):169-76.
    View in: PubMed
  73. Tarazi FI, Kula NS, Baldessarini RJ. Regional distribution of dopamine D4 receptors in rat forebrain. Neuroreport. 1997 Nov 10; 8(16):3423-6.
    View in: PubMed
  74. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997 Sep; 17(3):186-96.
    View in: PubMed
  75. Tarazi FI, Florijn WJ, Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 1997 Jun; 78(4):985-96.
    View in: PubMed
  76. Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997 Feb; 280(2):561-9.
    View in: PubMed
  77. Tarazi FI, Florijn WJ, Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 1996 Dec; 128(4):371-9.
    View in: PubMed
  78. Baldessarini RJ, Tarazi FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry. 1996 Mar-Apr; 3(6):301-25.
    View in: PubMed
  79. Cascella NG, Tarazi FI, Shirakawa O, Tamminga CA. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system. Psychopharmacology (Berl). 1994 Mar; 114(2):275-80.
    View in: PubMed
  80. Tarazi FI, Shirakawa O, Tamminga CA. Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects. Eur J Pharmacol. 1993 Feb 23; 232(1):71-7.
    View in: PubMed
  81. Ghosh TK, Mullaney JM, Tarazi FI, Gill DL. GTP-activated communication between distinct inositol 1,4,5-trisphosphate-sensitive and -insensitive calcium pools. Nature. 1989 Jul 20; 340(6230):236-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Tarazi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (286) concept(s)
_
Co-Authors
See all (8) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_